X4 Pharmaceuticals, Inc. (XFOR) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 4.22 |
| Open | 4.27 |
| Day High | 4.43 |
| Day Low | 4.12 |
| 52-Week High | 4.83 |
| 52-Week Low | 1.35 |
| Volume | 437,302 |
| Average Volume | 402,188 |
| Market Cap | 388.6M |
| PE | -1.98 |
| EPS | -2.08 |
| Moving Average 50 Days | 4.1 |
| Moving Average 200 Days | 3.77 |
| Change | -0.1 |
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
GlobeNewswire Inc.
Mar 04, 2026 12:00 PM GMT
BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the management team will participate in a fireside chat at the Leer
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Mar 02, 2026 9:30 PM GMT
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on February 27, 2026, the company issued inducement awar
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
GlobeNewswire Inc.
Feb 27, 2026 12:00 PM GMT
- Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today annou